구조모아 (StructureMoa)항암 chemical structure spider web
방문Guangzhou FineImmune Biotechnology Co.LTD.
tumor-specific TCR-T cells(Guangzhou FineImmune Biotechnology Co., LTD.)은 Solid Tumor 표적 세포·유전자 치료로, Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 50% (ClinicalTrials.gov NCT01343043). 차별점: novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM).
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Solid Tumor
Solid Tumor
Recruiting
2026-07-18
Data Confidence · Medium
Development Signal · Watch
CAR-T), tumor-infiltrating lymphocyte (TIL), and T cell receptor-
lipid nanoparticle delivery, we achieved efficient production of Allo-CAR T cells with high editin
novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM)
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
apoptosis and pyroptosis
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, on-target off-tumor toxicity, and the suppressive features of the TME
구조화 데이터
xenograft model
mouse
tumor growth inhibition
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Guangzhou FineImmune Biotechnology Co.LTD.
tumor-specific TCR-T cells(Guangzhou FineImmune Biotechnology Co., LTD.)은 Solid Tumor 표적 세포·유전자 치료로, Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 50% (ClinicalTrials.gov NCT01343043). 차별점: novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM).
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Solid Tumor
Solid Tumor
Recruiting
2026-07-18
Data Confidence · Medium
Development Signal · Watch
CAR-T), tumor-infiltrating lymphocyte (TIL), and T cell receptor-
lipid nanoparticle delivery, we achieved efficient production of Allo-CAR T cells with high editin
novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM)
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
apoptosis and pyroptosis
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, on-target off-tumor toxicity, and the suppressive features of the TME
구조화 데이터
xenograft model
mouse
tumor growth inhibition
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.